Search research articles
Contact Us
Filters
Showing results (261-270 of 371) with videos related to
Page
of 38
Sort By:
Cancer Cell
|
September 15, 2012
Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma
Stefano Monti, Bjoern Chapuy, Kunihiko Takeyama, et al.
The Journal of Molecular Diagnostics : JMD
|
December 16, 2023
Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing-Based Clonality Testing in B-Cell and Plasma Cell Neoplasms
Ying Liu, Caleb Ho, Wayne Yu, et al.
Blood Advances
|
October 1, 2020
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma
Paola Ghione, Promie Faruque, Neha Mehta-Shah, et al.
Haematologica
|
November 25, 2017
Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression
Sean I Tracy, Thomas M Habermann, Andrew L Feldman, et al.
Leukemia & Lymphoma
|
November 10, 2011
LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era
James R Cerhan, Yasodha Natkunam, Lindsay M Morton, et al.
Blood
|
January 15, 2025
Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype
Pallavi Galera, Deepika Dilip, Andriy Derkach, et al.
Blood
|
June 28, 2019
Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark
Justin Taylor, Michael Haddadin, Vivek A Upadhyay, et al.
Blood Cancer Journal
|
February 1, 2020
Correction: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma
Venkata Yellapantula, Malin Hultcrantz, Even H Rustad, et al.
Hematological Oncology
|
June 11, 2016
FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts
Hervé Ghesquières, Beth R Larrabee, Corinne Haioun, et al.
Nature
|
March 15, 2019
Efficacy of MEK inhibition in patients with histiocytic neoplasms
Eli L Diamond, Benjamin H Durham, Gary A Ulaner, et al.
Page
of 38
Search research articles
Search
Showing results (261-270 of 371) with videos related to
Sort By:
Page
of 38
Cancer Cell
|
September 15, 2012
Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma
Stefano Monti, Bjoern Chapuy, Kunihiko Takeyama, et al.
The Journal of Molecular Diagnostics : JMD
|
December 16, 2023
Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing-Based Clonality Testing in B-Cell and Plasma Cell Neoplasms
Ying Liu, Caleb Ho, Wayne Yu, et al.
Blood Advances
|
October 1, 2020
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma
Paola Ghione, Promie Faruque, Neha Mehta-Shah, et al.
Haematologica
|
November 25, 2017
Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression
Sean I Tracy, Thomas M Habermann, Andrew L Feldman, et al.
Leukemia & Lymphoma
|
November 10, 2011
LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era
James R Cerhan, Yasodha Natkunam, Lindsay M Morton, et al.
Blood
|
January 15, 2025
Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype
Pallavi Galera, Deepika Dilip, Andriy Derkach, et al.
Blood
|
June 28, 2019
Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark
Justin Taylor, Michael Haddadin, Vivek A Upadhyay, et al.
Blood Cancer Journal
|
February 1, 2020
Correction: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma
Venkata Yellapantula, Malin Hultcrantz, Even H Rustad, et al.
Hematological Oncology
|
June 11, 2016
FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts
Hervé Ghesquières, Beth R Larrabee, Corinne Haioun, et al.
Nature
|
March 15, 2019
Efficacy of MEK inhibition in patients with histiocytic neoplasms
Eli L Diamond, Benjamin H Durham, Gary A Ulaner, et al.
Page
of 38